TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33624010

Group type: EXPERIMENTAL
Intervention: Symptom survey
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Work productivity and activity index questionnaire
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: 6-minute walk test
Number of subjects: 118
Study: 33624026

Group type: EXPERIMENTAL
Intervention: Routine fasting (n=389, average 42 years of fasting)
Number of subjects: 1957

Group type: EXPERIMENTAL
Intervention: Routine fasting (n=389)
Number of subjects: 1957

Group type: COMPARATOR
Intervention: Non-fasters (n=1568)
Number of subjects: 1957
Study: 33624028

Group type: EXPERIMENTAL
Intervention: Elevated neutrophil count >7.8 × 10^9/L
Number of subjects: 2034

Group type: EXPERIMENTAL
Intervention: Neutrophil-to-lymphocyte ratio (NL-ratio) >5
Number of subjects: 2034

Group type: EXPERIMENTAL
Intervention: Neutrophil-count/creatinine ratio
Number of subjects: 2034

Group type: EXPERIMENTAL
Intervention: NL-ratio/creatinine ratio
Number of subjects: 2034

Group type: EXPERIMENTAL
Intervention: hsCRP
Number of subjects: 2034

Group type: EXPERIMENTAL
Intervention: Higher GRACE score 1.0/NL-ratio
Number of subjects: 2034
Study: 33624040

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33624069

Group type: EXPERIMENTAL
Intervention: Baseline CV risk assessment using SCORE
Number of subjects: 1324

Group type: COMPARATOR
Intervention: Individual risk factors
Number of subjects: 1324
Study: 33624130

Group type: EXPERIMENTAL
Intervention: One hour of additional sleep per night
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Adhering to the sleep duration recommendation (9-12 hours)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Sleep duration
Number of subjects: 406
Study: 33624223

Group type: EXPERIMENTAL
Intervention: Plasma vanin-1 levels measured by ELISA in trauma patients
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Plasma vanin-1 levels in patients with sepsis
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Plasma vanin-1 at day 1 after trauma
Number of subjects: 426
Study: 33624233

Group type: EXPERIMENTAL
Intervention: LY3022855 (anti-CSF-1R monoclonal antibody) 2.5 mg/kg QW, 0.3 mg/kg QW, 0.6 mg/kg QW, 1.25 mg/kg Q2W, 1.25 mg/kg QW, 100 mg QW, 150 mg QW
Number of subjects: 52
Study: 33624513

Group type: EXPERIMENTAL
Intervention: Childhood cancer survivors (CCSs)
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Population-based sample (GHS)
Number of subjects: 1002
Study: 33625039

Group type: EXPERIMENTAL
Intervention: Cell and gene therapy for HIV disease, specific details on dosage and duration not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vectored passive immunity, B cell engineering, T cell engineering, specific details on dosage and duration not available.
Number of subjects: 0
Study: 33625060

Group type: EXPERIMENTAL
Intervention: Cafedrine hydrochloride (200 mg) and theodrenaline hydrochloride (10 mg) in 2 ml (C/T)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ephedrine
Number of subjects: 0
Study: 33625125

Group type: EXPERIMENTAL
Intervention: Endoscopic mucosal resection (EMR) for PA-LNPCPs
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Margin thermal ablation at SC1
Number of subjects: 158

Group type: COMPARATOR
Intervention: Endoscopic mucosal resection (EMR) for naive large nonpedunculated colorectal polyps (N-LNPCPs)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Endoscopic mucosal resection (EMR) for PA-LNPCPs (adjusted for 2-stage EMR)
Number of subjects: 158
Study: 33625361

Group type: EXPERIMENTAL
Intervention: AFib 2gether mobile app
Number of subjects: 0
Study: 33625366

Group type: EXPERIMENTAL
Intervention: Mindfulness-based strategies delivered in real time
Number of subjects: 0
Study: 33625371

Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) administered intravenously at a loading dose of 30 mg/kg over 15 minutes, followed by a continuous infusion of 1 mg/kg/hour over the next 12 hours.
Number of subjects: 245

Group type: COMPARATOR
Intervention: Placebo (0.9% saline) administered intravenously in an identical manner to VPA.
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA)
Number of subjects: 245
Study: 33625372

Group type: EXPERIMENTAL
Intervention: Personalized, automated caregiver mobile phone-delivered text message reminders for vaccination visits.
Number of subjects: 1961

Group type: COMPARATOR
Intervention: Standard of care (health worker providing child vaccination home-based records and verbal instructions).
Number of subjects: 1961
Study: 33625541

Group type: EXPERIMENTAL
Intervention: Lateral trochlear lengthening osteotomy
Number of subjects: 6
Study: 33625721

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/day for 16 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sitagliptin treatment
Number of subjects: 32
Study: 33625743

Group type: EXPERIMENTAL
Intervention: Percutaneous osteosynthesis
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Cable pin system (open or percutaneous surgery)
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Biodegradable implants
Number of subjects: 564

Group type: COMPARATOR
Intervention: Patellectomy with advancement of vastus medialis obliquus surgery
Number of subjects: 564

Group type: COMPARATOR
Intervention: New intraoperative reduction technique
Number of subjects: 564

Group type: COMPARATOR
Intervention: Modified tension band technique
Number of subjects: 564

Group type: COMPARATOR
Intervention: Adjustable patella claws and absorbable suture
Number of subjects: 564
Study: 33625762

Group type: EXPERIMENTAL
Intervention: Specific dual chamber pacemaker with SafeR algorithm activated
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Post-TAVI early high-grade atrioventricular block
Number of subjects: 197

Group type: COMPARATOR
Intervention: Oversizing
Number of subjects: 197

Group type: COMPARATOR
Intervention: High-grade atrioventricular block during TAVI
Number of subjects: 197

Group type: COMPARATOR
Intervention: Early high-grade atrioventricular block (within 6 days)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Self-expanding prosthesis
Number of subjects: 197

Group type: COMPARATOR
Intervention: Prior right bundle branch block
Number of subjects: 197

Group type: COMPARATOR
Intervention: Low implantation
Number of subjects: 197

Group type: COMPARATOR
Intervention: New or wider left bundle branch block and lengthening of PR interval
Number of subjects: 197
Study: 33625799

Group type: EXPERIMENTAL
Intervention: Lung diffusing capacity for nitric oxide and carbon monoxide (DLNO and DLCO) measurements post-COVID-19 infection.
Number of subjects: 0
Study: 33625888

Group type: EXPERIMENTAL
Intervention: International camps for education and psychosocial support, details on dosage and duration not available.
Number of subjects: 0
Study: 33626238

Group type: COMPARATOR
Intervention: Dacomitinib
Number of subjects: 6

Group type: COMPARATOR
Intervention: Osimertinib
Number of subjects: 6

Group type: COMPARATOR
Intervention: Bevacizumab + Erlotinib
Number of subjects: 6

Group type: COMPARATOR
Intervention: Gefitinib + Chemotherapy
Number of subjects: 6

Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 6

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 6
Study: 33626251

Group type: EXPERIMENTAL
Intervention: Risdiplam (0.08 mg/kg/day) in low-dose cohort
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Risdiplam (0.2 mg/kg/day) in high-dose cohort
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 21
Study: 33626253

Group type: EXPERIMENTAL
Intervention: Idecabtagene vicleucel (ide-cel)
Number of subjects: 140
Study: 33626360

Group type: EXPERIMENTAL
Intervention: 10-2 test
Number of subjects: 630

Group type: COMPARATOR
Intervention: C24-2 test
Number of subjects: 630

Group type: COMPARATOR
Intervention: Pattern standard deviation values from C24-2 test
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Pattern standard deviation values from 10-2 test
Number of subjects: 630
Study: 33626457

Group type: EXPERIMENTAL
Intervention: Fever-range whole body hyperthermia (FRWBH) scheduled weekly during re-irradiation; 5 patients received all cycles of FRWBH.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fever-range whole body hyperthermia (FRWBH)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Re-irradiation using volumetric arc hyperfractionated radiotherapy with bi-daily 1.2 Gray (Gy) single fractions and a total dose of 66 Gy to all macroscopic tumor lesions; concomitant chemotherapy mostly with cisplatin (7 patients).
Number of subjects: 10
Study: 33626891

Group type: EXPERIMENTAL
Intervention: Psychological stress (assessed using the Perceived Stress Scale - PSS-14)
Number of subjects: 110
Study: 33626896

Group type: EXPERIMENTAL
Intervention: Restricted mean survival time methods
Number of subjects: 0

Group type: COMPARATOR
Intervention: Proportional hazards methods
Number of subjects: 0
Study: 33627058

Group type: EXPERIMENTAL
Intervention: Evidence-based shared decision-making tool (brochure, website, and recorded patient vignettes) for patients with PAD.
Number of subjects: 0
Study: 33627066

Group type: EXPERIMENTAL
Intervention: Presence of necrotic core in carotid plaque
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: CKD
Number of subjects: 465
Study: 33627067

Group type: EXPERIMENTAL
Intervention: Pain assessment
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Agitation-sedation assessment
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Delirium assessment
Number of subjects: 387

Group type: COMPARATOR
Intervention: Physician perception of pain assessment
Number of subjects: 387

Group type: COMPARATOR
Intervention: Physician perception of agitation-sedation assessment
Number of subjects: 387

Group type: COMPARATOR
Intervention: Physician perception of delirium assessment
Number of subjects: 387
Study: 33627095

Group type: EXPERIMENTAL
Intervention: Presence of Haemophilus influenzae (Hi) at stable timepoints
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Presence of Moraxella catarrhalis (Mcat) at stable timepoints
Number of subjects: 255

Group type: COMPARATOR
Intervention: Hi-negative at previous stable timepoints
Number of subjects: 255

Group type: COMPARATOR
Intervention: Mcat-negative at previous stable timepoints
Number of subjects: 255
Study: 33627105

Group type: EXPERIMENTAL
Intervention: Antifibrotic therapy
Number of subjects: 209
Study: 33627164

Group type: EXPERIMENTAL
Intervention: Moxetumomab pasudotox (40 µg/kg intravenously on Days 1, 3, and 5 of each 28-day cycle for up to six cycles)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Moxetumomab pasudotox
Number of subjects: 80
Study: 33627169

Group type: EXPERIMENTAL
Intervention: Helmet CPAP treatment
Number of subjects: 306
Study: 33627179

Group type: EXPERIMENTAL
Intervention: Exercise training intervention (6-month-long, four times a week including endurance, strength, and high-intensity training)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maximal exercise capacity test and tests of muscular strength
Number of subjects: 0
Study: 33627193

Group type: EXPERIMENTAL
Intervention: Continuous erector spinae plane block (ESP)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intercostal nerve block (ICNB)
Number of subjects: 24
Study: 33627192

Group type: EXPERIMENTAL
Intervention: Amoxicillin treatment in a randomized controlled trial
Number of subjects: 79

Group type: COMPARATOR
Intervention: Children with comorbidities
Number of subjects: 79

Group type: COMPARATOR
Intervention: Children without comorbidities
Number of subjects: 79
Study: 33627234

Group type: EXPERIMENTAL
Intervention: Text messaging intervention
Number of subjects: 21
Study: 33627313

Group type: EXPERIMENTAL
Intervention: Endoscopy in patients with COVID-19
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Upper GI abnormalities
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Lower GI endoscopies
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: D-dimers >1850 ng/mL
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Presence of GI symptoms
Number of subjects: 106
Study: 33627317

Group type: EXPERIMENTAL
Intervention: Serum calcification propensity measurement using nephelometry
Number of subjects: 0

Group type: COMPARATOR
Intervention: Retrospective analysis of macrovascular events
Number of subjects: 0
Study: 33627355

Group type: EXPERIMENTAL
Intervention: Single high-sensitivity cardiac troponin T (hs-cTnT) measurement <5 ng/L
Number of subjects: 1711

Group type: COMPARATOR
Intervention: Original HEART score
Number of subjects: 1711

Group type: COMPARATOR
Intervention: Modified HEART score
Number of subjects: 1711

Group type: COMPARATOR
Intervention: Single rule-out, original HEART group, modified HEART group
Number of subjects: 1711
Study: 33627400

Group type: EXPERIMENTAL
Intervention: Mini-invasive radial balloon aortic valvuloplasty (BAV)
Number of subjects: 330
Study: 33627448

Group type: EXPERIMENTAL
Intervention: COVID-19 related practices among dental hygienists
Number of subjects: 0
Study: 33627495

Group type: EXPERIMENTAL
Intervention: CT-based SVD biomarkers (white matter hypodensities, lacunes, brain atrophy, composite SVD burden score)
Number of subjects: 864

Group type: EXPERIMENTAL
Intervention: Revised ICH score with SVD markers
Number of subjects: 864

Group type: COMPARATOR
Intervention: Revised ICH score without SVD markers
Number of subjects: 864
Study: 33627609

Group type: EXPERIMENTAL
Intervention: Cytokine adsorption using the CytoSorb adsorber during V-V ECMO.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (V-V ECMO without cytokine adsorption).
Number of subjects: 18
Study: 33628143

Group type: EXPERIMENTAL
Intervention: Liwen procedure for myocardial biopsy
Number of subjects: 17
Study: 33628355

Group type: EXPERIMENTAL
Intervention: Chronic Pain Behavioral Pain Scale (CBPS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Numeric Rating Scale (NRS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interrater reliability (CBPS scores)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concurrent validity (preprocedure measurements)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concurrent validity (postprocedure measurements)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Construct validity
Number of subjects: 0
Study: 33628776

Group type: EXPERIMENTAL
Intervention: Specific training course for competency in arterial blood gas (ABG) sampling
Number of subjects: 56
Study: 33628834

Group type: EXPERIMENTAL
Intervention: Hybrid Closed Loop (HCL) insulin delivery system with integrated continuous glucose monitoring (CGM)
Number of subjects: 6
Study: 33629188

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements (ONS) with warming and cooling sensations (hot tropical ginger, hot mango, cool red fruits, cool lemon, neutral)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Patients with taste alterations (TAs)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Patients without taste alterations (TAs)
Number of subjects: 50
Study: 33629225

Group type: EXPERIMENTAL
Intervention: LumiraDx SARS-CoV-2 antigen test (12-min nasal swab)
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: LumiraDx SARS-CoV-2 antigen test (nasopharyngeal swab)
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: User error rate of the test system
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Detection of samples within 33 rt-PCR cycles
Number of subjects: 512
Study: 33629404

Group type: EXPERIMENTAL
Intervention: Paravertebral anaesthesia
Number of subjects: 614
Study: 33629410

Group type: EXPERIMENTAL
Intervention: Necklace-ECG (palm position)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Necklace-ECG (chest position)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Automatic AF detection algorithm (palm position)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Automatic AF detection algorithm (chest position)
Number of subjects: 145
Study: 33629819

Group type: EXPERIMENTAL
Intervention: Ticagrelor (0.1 mg/kg <6 months; 0.2 mg/kg ≥6 to <24 months)
Number of subjects: 21
Study: 33630047

Group type: EXPERIMENTAL
Intervention: Total body fat (TBF)
Number of subjects: 90
Study: 33630063

Group type: EXPERIMENTAL
Intervention: Sipuleucel-T treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control antigens
Number of subjects: 0
Study: 33630272

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) therapy
Number of subjects: 1789

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) Tocilizumab (TCZ) therapy
Number of subjects: 1789

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) therapy with known reasons for discontinuation
Number of subjects: 1789
Study: 33630275

Group type: EXPERIMENTAL
Intervention: Daratumumab 16 mg/kg monotherapy
Number of subjects: 293
Study: 33630503

Group type: EXPERIMENTAL
Intervention: Health service usability
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Trusting relationships with individual providers
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Management of time demands and physical access challenges
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Configuration of connections to multiple health services
Number of subjects: 66
Study: 33630532

Group type: EXPERIMENTAL
Intervention: Mindful Moms intervention (12-week program involving mindful physical activity using prenatal yoga)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mindful Moms intervention
Number of subjects: 0
Study: 33630535

Group type: EXPERIMENTAL
Intervention: Financial stress (in men)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Financial stress (in women)
Number of subjects: 0
Study: 33630644

Group type: EXPERIMENTAL
Intervention: Cocaine-related cues
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nondrug-related pleasant images
Number of subjects: 0
Study: 33630747

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sitting Time
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nutritional Habits (mMDS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol Consumption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sleeping Quality
Number of subjects: 0
Study: 33630808

Group type: EXPERIMENTAL
Intervention: Intralipid infusion (100-mL intravenous lipid emulsion)
Number of subjects: 58

Group type: COMPARATOR
Intervention: HFLCD alone (control)
Number of subjects: 58
Study: 33631079

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33631349

Group type: EXPERIMENTAL
Intervention: Accelerated neuromodulation therapy
Number of subjects: 0
Study: 33631774

Group type: EXPERIMENTAL
Intervention: Once-weekly prophylaxis with nonacog alfa 100 IU/kg (12 months)
Number of subjects: 25

Group type: COMPARATOR
Intervention: On-demand nonacog alfa (6 months; dose at investigator's discretion)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Once-weekly prophylaxis with nonacog alfa
Number of subjects: 25
Study: 33631781

Group type: EXPERIMENTAL
Intervention: BN navigator assistance
Number of subjects: 100

Group type: COMPARATOR
Intervention: No unmet BNs
Number of subjects: 100

Group type: COMPARATOR
Intervention: Pre-study adherence rates
Number of subjects: 100
Study: 33632138

Group type: EXPERIMENTAL
Intervention: Handgrip strength
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Gait speed
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ultrasound quadriceps
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bioelectrical Impedance Analysis (BIA)
Number of subjects: 40
Study: 33632149

Group type: EXPERIMENTAL
Intervention: WMH pathology
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: MTA pathology
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Left hemispheric stroke
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Stroke lesion volume
Number of subjects: 231
Study: 33632155

Group type: EXPERIMENTAL
Intervention: CAR-T cell infusion
Number of subjects: 13
Study: 33632171

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 positive participants
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Male participants with SARS-CoV-2 antibodies
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Female participants with SARS-CoV-2 antibodies
Number of subjects: 467
Study: 33632175

Group type: EXPERIMENTAL
Intervention: Experiencing four or more ACEs
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Experiencing community violence or family distress
Number of subjects: 889
Study: 33632205

Group type: EXPERIMENTAL
Intervention: Diabetes self-management intervention
Number of subjects: 57
Study: 33632262

Group type: EXPERIMENTAL
Intervention: BCI-FES hand therapy system
Number of subjects: 8
Study: 33632271

Group type: EXPERIMENTAL
Intervention: Provisional questionnaire for ICU survivors
Number of subjects: 395

Group type: COMPARATOR
Intervention: Control group (non-ICU-treated)
Number of subjects: 395
Study: 33632313

Group type: EXPERIMENTAL
Intervention: Pain-guided activity (PGA)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Pain-free activity (PFA)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: PGA and PFA groups
Number of subjects: 15
Study: 33632330

Group type: EXPERIMENTAL
Intervention: HENRY intervention (Health, Exercise, Nutrition for the Really Young)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 117
Study: 33632492

Group type: EXPERIMENTAL
Intervention: Different plaque imaging techniques
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33632707

Group type: EXPERIMENTAL
Intervention: Obesity measures (BMI, WC, HC, WHR)
Number of subjects: 2493

Group type: EXPERIMENTAL
Intervention: Hyperinsulinemia measures (insulin, HOMA-IR, HOMA-%β)
Number of subjects: 2493
Study: 33632753

Group type: EXPERIMENTAL
Intervention: Automated assay measuring serum concentrations of GFAP and UCH-L1
Number of subjects: 1760
Study: 33632755

Group type: EXPERIMENTAL
Intervention: Digital health solutions
Number of subjects: 0
Study: 33632769

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 6 min walk test
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: log to base 10 N-terminal pro-brain natriuretic peptide
Number of subjects: 42
Study: 33632775

Group type: EXPERIMENTAL
Intervention: Mobocertinib (TAK-788)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33632799

Group type: EXPERIMENTAL
Intervention: Asthma
Number of subjects: 11243

Group type: EXPERIMENTAL
Intervention: Asthma+COPD
Number of subjects: 11243

Group type: EXPERIMENTAL
Intervention: COPD
Number of subjects: 11243

Group type: COMPARATOR
Intervention: Overall findings
Number of subjects: 11243
Study: 33632874

Group type: EXPERIMENTAL
Intervention: NLG207 (Formerly CRLX101) in combination with Enzalutamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enzalutamide alone
Number of subjects: 0